title: Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.
authors.affiliation: U.O. Gastroenterologia ed Epatologia, Azienda Ospedaliera, Universitaria Pisana, Pisa, Italy. brunetto@med-club.com
authors.forename: Maurizia Rossana
authors.initials: MR
authors.lastname: Brunetto
authors.forename: Filippo
authors.initials: F
authors.lastname: Oliveri
authors.forename: Piero
authors.initials: P
authors.lastname: Colombatto
authors.forename: Barbara
authors.initials: B
authors.lastname: Coco
authors.forename: Pietro
authors.initials: P
authors.lastname: Ciccorossi
authors.forename: Ferruccio
authors.initials: F
authors.lastname: Bonino
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006513:Hepatitis B e Antigens / Q000032:analysis*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D007372:Interferons; C100416:peginterferon alfa-2a